Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring.
We investigated whether a woman's periconceptional use of a multivitamin containing folic acid was associated with a reduced risk for delivering offspring with a conotruncal heart defect or a limb deficiency. Data were derived from a population-based case-control study of fetuses and liveborn infants with conotruncal or limb defects among a 1987-88 cohort of births in California. Telephone interviews were conducted with mothers of 207 (87.0% of eligible) conotruncal cases, 178 (82.0%) limb defect cases, and of 481 (76.2%) randomly selected liveborn nonmalformed control infants. Reduced risks were observed for maternal use of multivitamins containing folic acid from one month before until two months after conception. Odds ratios and 95% confidence intervals for any compared to no multivitamin use were 0.70 (0.46-1.1) for conotruncal defects and 0.64 (0.41-1.0) for limb defects. Controlling for maternal race/ethnicity, age, education, gravidity, alcohol use, and cigarette use resulted in a further reduction to the odds ratio for conotruncal defects, 0.53 (0.34-0.85), but not for limb defects. Among non-vitamin using women, consumption of cereal containing folic acid was also associated with reduced risk for both defects. Women who take multivitamins have 30-35% lower risk of delivering offspring with either conotruncal or limb defects. This association may not be attributable to folic acid specifically, but may be a consequence of other multivitamin components, or some unknown behaviors that highly correlate with regular use of a multivitamin. However, should the association prove causal, it offers an important opportunity for preventing thousands of serious birth defects.
Shaw
G M
GM
March of Dimes Birth Defects Foundation, Califorrnia Birth Defects Monitoring Program, Emeryville 94608, USA.
O'Malley
C D
CD
Wasserman
C R
CR
Tolarova
M M
MM
Lammer
E J
EJ
D016022:Case-Control Studies; D000013:Congenital Abnormalities / Q000517:prevention & control*; D005260:Female; D005306:Fertilization; D005492:Folic Acid / Q000627:therapeutic use*; D006330:Heart Defects, Congenital / Q000517:prevention & control*; D006801:Humans; D007231:Infant, Newborn; D017880:Limb Deformities, Congenital; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D014815:Vitamins / Q000008:administration & dosage*
D014815:Vitamins; D005492:Folic Acid